This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    LP0145-2240
Previous Study | Return to List | Next Study

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05923099
Recruitment Status : Recruiting
First Posted : June 28, 2023
Last Update Posted : April 9, 2024
Sponsor:
Information provided by (Responsible Party):
LEO Pharma

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The purpose of this trial is to test different doses of the trial medicine (LEO 138559) at treating moderate to severe atopic dermatitis in adults. There will be 4 different doses, that will also be compared to a placebo (a dummy medicine that doesn't contain the active ingredient of LEO 138559). Each participant will be randomly assigned to one of the 4 doses of LEO 138559 or placebo. In all arms, injections of placebo may be used to mask the different doses.

The trial will last up to 36 weeks, including a screening/washout period (up to 4 weeks), a treatment period (16 weeks), and a follow up period (16 weeks). The participants will visit the clinic 17 times. For the first 4 weeks of the treatment period, participants will visit the clinic every week. For the next 12 weeks of the treatment period, participants will visit the clinic every 2 weeks. For the 16 week follow up period, participants will visit the clinic every 4 weeks.

The treatments will be given to the participants by staff at the clinic. They are given as an injection just under the skin.

At each visit the doctor will check the participants atopic dermatitis and if they have had any side effects. Participants will also complete an electronic diary every day about their atopic dermatitis and quality of life.


Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: LEO 138559 Drug: Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-site, Parallel-group, Dose-finding Trial to Evaluate the Efficacy and Safety of Different Doses of Subcutaneously Administered LEO 138559 in Adult Subjects With Moderate-to-severe Atopic Dermatitis
Actual Study Start Date : September 20, 2023
Estimated Primary Completion Date : December 9, 2024
Estimated Study Completion Date : March 31, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Dose regimen 1
Dose A every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
 Drug: LEO 138559
LEO 138559 given by injection just under the skin
Experimental: Dose regimen 2
Dose B every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
 Drug: LEO 138559
LEO 138559 given by injection just under the skin
Experimental: Dose regimen 3
Dose A every week from Week 0 to Week 3, then dose C every 2 weeks from Week 4 to Week 16
 Drug: LEO 138559
LEO 138559 given by injection just under the skin
Experimental: Dose regimen 4
Dose C every week from Week 0 to Week 3, then dose D every 2 weeks from Week 4 to Week 16
 Drug: LEO 138559
LEO 138559 given by injection just under the skin
Placebo Comparator: Placebo regimen
Placebo every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
 Drug: Placebo
Placebo given by injection just under the skin


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percent change in Eczema Area and Severity Index (EASI) score [ Time Frame: From baseline to Week 16 ]
    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe, and/or more extensive condition.


Secondary Outcome Measures :
  1. Number of treatment-emergent adverse events (TEAEs) recorded for each subject [ Time Frame: From baseline (Week 0) to Week 16 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed and dated informed consent has been obtained prior to any protocol related procedures.
  • 18-75 years old (both included) at screening (Visit 1).
  • Willingness to comply with the clinical trial protocol.

  • At screening, diagnosis of atopic dermatitis (AD) as defined by the Hanifin and Rajka (1980) criteria for AD.

    • History of AD for ≥1 year.
  • Subjects who have a recent history (within 12 months before screening) with documented inadequate response to treatment with topical corticosteroid(s) (TCS) (±topical calcineurin inhibitor(s) (TCI) as appropriate) or for whom these topical AD treatments are medically inadvisable (e.g. due to important side effects or safety risks).
  • Eczema Area and Severity Index (EASI) score ≥12 at screening and ≥16 at baseline.
  • validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score ≥3 at screening and baseline.
  • Body Surface Area (BSA) of AD involvement ≥10% at screening and baseline.
  • Atopic Dermatitis Symptom Diary (ADSD) Worst Itch score (weekly average) ≥4 at baseline.
  • A woman of childbearing potential must use a highly effective form of birth control throughout the trial and for at least 18 weeks after last administration of IMP.

Exclusion Criteria:

  • Major surgery within 8 weeks prior to screening, or planned inpatient surgery or hospitalization during the trial period.
  • Active dermatologic condition that could confound the diagnosis of AD or interfere with assessment of the treatment (e.g. scabies, contact dermatitis, rosacea, urticaria, or psoriasis).

  • History of cancer, with the following exceptions:

    • Subjects who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the subject is in remission and curative therapy was completed at least 12 months prior to screening.
    • Subjects who have had other malignancies are eligible provided that the subject is in remission and curative therapy was completed at least 5 years prior to screening
  • History of or current immunodeficiency syndrome.
  • History of anaphylaxis following any biologic therapy.
  • History of clinically significant infection within 4 weeks prior to baseline which, in the opinion of the investigator, may compromise the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the subject's ability to participate in the trial.
  • Skin infection within 7 days prior to baseline
  • Positive HBsAg or positive anti-HCV AND positive HCV RNA at screening.
  • History of HIV infection or positive HIV serology at screening.
  • Evidence of active or latent tuberculosis according to local standard of care for patients requiring initiation of a biologic treatment.
  • ALT or AST level ≥2.0 times the ULN at screening.
  • History of attempted suicide or is at significant risk of suicide (either in the opinion of the investigator or defined as a "yes" to suicidal ideation questions no. 4 or 5 or answering "yes" to suicidal behavior on the C-SSRS Screening version).
  • Known or suspected hypersensitivity to any component(s) of the IMP.

  • Any disorder at screening and/or baseline, which is not stable in the opinion of the investigator, and could:

    • Affect the safety of the subject throughout the trial.
    • Influence the results of the trial.
    • Impede the subject's ability to complete the trial.

  • Any significant abnormal finding at screening and/or baseline which may, in the opinion of the investigator:

    • Put the subject at risk because of their participation in the trial.
    • Influence the results of the trial.
    • Influence the subject's ability to complete the trial.
  • Current or recent chronic alcohol or drug abuse, or any other condition associated with poor compliance as judged by the investigator.
  • Women who are pregnant or breastfeeding.
  • Previous treatment with LEO 138559.
  • Previous exposure to fezakinumab (anti-IL-22 Ab).
  • Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, corticosteroids (steroid eyedrops and inhaled or intranasal steroids are allowed), or JAK inhibitors within 28 days or 5 half-lives prior to baseline, whichever is longer.
  • Use of tanning beds or phototherapy, within 4 weeks prior to baseline.
  • Receipt of blood products within 28 days prior to screening.

  • Treatment with:

    • Any marketed or investigational biologic agents within 3 months or 5 half-lives, whichever is longer, prior to baseline.
    • Any cell-depleting agents including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
  • Treatment with TCS, TCI, topical PDE-4 inhibitors, topical JAK inhibitors, or other medicated topical treatments within 7 days prior to baseline.
  • Receipt of live attenuated vaccines 30 days prior to baseline.
  • Treatment with any non-marketed drug substance (that is, an agent which has not yet been made available for clinical use following registration) within the last 4 weeks or 5 half lives prior to randomization, whichever is longer.
  • Current participation in any other interventional clinical trial.
  • Previously randomized in this clinical trial.
  • Employees of the trial site, or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.
  • Subjects who are legally institutionalized.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05923099


Contacts
Layout table for location contacts
Contact: Clinical Disclosure (+1) 877-557-1168 clinicaltrialscontactus@leo-pharma.com

Locations
Show Show 69 study locations
Sponsors and Collaborators
LEO Pharma
Investigators
Layout table for investigator information
Study Director: Medical Expert LEO Pharma
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: LEO Pharma
ClinicalTrials.gov Identifier: NCT05923099    
Other Study ID Numbers: LP0145-2240
U1111-1286-0955 ( Other Identifier: World Health Organization (WHO) )
2022-500777-14-00 ( Other Identifier: European Medicines Agency (EMA) )
First Posted: June 28, 2023    Key Record Dates
Last Update Posted: April 9, 2024
Last Verified: January 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Access Criteria: De-identified Individual Participant Data can be made available to researchers and is subject to approved scientifically sound research proposal and signed data-sharing agreement.
URL: https://www.leopharmatrials.com/en/for-professionals

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
 Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases